In the training cohort (cetuximab-based), the CD274-rs2297137-G allele was associated with worse tumor response (56% AA vs. 19% GA vs. 16% GG; p = 0.029), the CTLA4-rs231777-CT genotype with shorter PFS (multivariate HR: 1.76; p = 0.019), and the CD24-rs52812045-AA genotype with shorter median PFS and OS (multivariate PFS HR:3.18, p = 0.009; OS: HR:4.93, p = 0.001). Here, CD274 is linked to neoplasm.